Anemia in chronic kidney disease. Anemia in other chronic diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: Participants will receive routine hemodialysis care along with oral administration of N-acetylcysteine at a dose of 600 mg twice daily (morning and evening) for 12
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: Chronic hemodialysis patients (more than 3 months) with uremic anemia (Hb < 11 g/dL) Age: 35–65 years old Written informed consent Ability to take medication
Exclusion criteria
Exclusion criteria: History of allergy to N-acetylcysteine Severe hepatic failure Recent use of high-dose antioxidant drugs Active infection Pregnancy, or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood hemoglobin level. Timepoint: Measurement at baseline (before the start of the intervention) and at the end of week twelve after the start of the intervention. Method of measurement: The calibrated and validated hematology analyzer.;Serum ferritin. Timepoint: Measurement at baseline (before the start of the intervention) and at the end of week twelve after the start of the intervention. Method of measurement: Using ELISA.;Transferrin saturation index. Timepoint: Measurement at baseline (before the start of the intervention) and at the end of week twelve after the start of the intervention. Method of measurement: Measurement of serum iron and total iron-binding capacity (TIBC) using a calibrated and validated biochemical autoanalyzer.;Mean corpuscular volume (MCV). Timepoint: Measurement at baseline (before the start of the intervention) and at the end of week twelve after the start of the intervention. Method of measurement: Calibrated and validated hematology analyzer.;Hematocrit. Timepoint: Measurement at baseline (before the start of the intervention) and at the end of week twelve after the start of the intervention. Method of measurement: Calibrated and validated hematology analyzer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythropoietin. Timepoint: EPO dose measured weekly throughout the 12 weeks of the study. Method of measurement: Calculation and recording of the weekly EPO dose prescribed for each patient based on the treating physician’s orders and medication records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Amiri
Ahvaz University of Medical Sciences
Outcome results
None listed